Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 1, 2014, Pages 30-35

  Kalayjian, Robert C ^a,d   Wu, Kunling ^b   Evans, Scott ^b   Clifford, David B ^c   Pallaki, Muraldihar ^d   Currier, Judith S ^e   Smryzynski, Marlene ^b,f  

^a METROHEALTH MEDICAL CENTER   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

HIV Associated neurocognitive disorders; neurocognitive impairment; proteinuria; vascular disease

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; PROTEIN; TENOFOVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; COGNITIVE DEFECT; COHORT ANALYSIS; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIGIT SYMBOL SUBSTITUTION TEST; DISEASE ASSOCIATION; FEMALE; GENERALIZED ESTIMATING EQUATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VASCULAR DISEASE; WECHSLER INTELLIGENCE SCALE; CLINICAL TRIAL; GLOMERULUS FILTRATION RATE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MILD COGNITIVE IMPAIRMENT; MULTIVARIATE ANALYSIS; PSYCHOLOGY; QUESTIONNAIRE; STATISTICAL MODEL; URINE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MILD COGNITIVE IMPAIRMENT; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PROTEINURIA; QUESTIONNAIRES;

EID: 84906060817     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000237     Document Type: Conference Paper

References (52)

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-Associated neurocognitive disorders. Neurology. 2007;69: 1789-1799.
2. Cohen RA, Boland R, Paul R, et al. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS. 2001;15:341-345.
3. Ferrando S, van Gorp W, McElhiney M, et al. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS. 1998;12:F65-F70.
4. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-Associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
5. Robertson K, Jiang H, Kumwenda J, et al. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis. 2012;55: 868-876.
6. Suarez S, Baril L, Stankoff B, et al. Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. AIDS. 2001;15:195-200.
7. Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-Associated neurocognitive impairment. AIDS. 1999;13:1889-1897.
8. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007; 21:1915-1921.
9. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24: 1243-1250.
10. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antire-troviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359-1366.
11. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV seros-tatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73:1292-1299.
12. Wright EJ, Grund B, Robertson K, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology. 2010;75:864-873.
13. Foley J, Ettenhofer M, Wright MJ, et al. Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol. 2010;24:265-285.
14. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-Associated neurocognitive disorder. Neurology. 2012;78:485-492.
15. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423-429.
16. Perkovic V, Verdon C, Ninomiya T, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-Analysis. PLoS Med. 2008;5:e207.
17. Bouchi R, Babazono T, Yoshida N, et al. Association of albuminuria and reduced estimated glomerular filtration rate with incident stroke and coronary artery disease in patients with type 2 diabetes. Hypertens Res. 2010;33:1298-1304.
18. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-Analysis. Lancet. 2010;375:2073-2081.
19. Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis. 2010; 56:872-882.
20. Choi AI, Li Y, Deeks SG, et al. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121:651-658.
21. Wyatt CM, Hoover DR, Shi Q, et al. Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr. 2010;55:73-77.
22. Gardner LI, Holmberg SD, Williamson JM, et al. Development of pro-teinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:203-209.
23. Smurzynski M, Collier AC, Koletar SL, et al. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials. 2008;9:269-282.
24. Heaton RK, Miller SW, Taylor MJ, et al. Revised Comprehensive Norms for an Expanded Halstead-reitan Battery: Demographically Adjusted Neuro-phychological Norms for African American and Caucasian Adults. Professional Manual. Lutz, FL: Psychological Assessment Resources, Inc.; 2006.
25. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42:617-622.
26. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
27. Garg P, Rabelink T. Glomerular proteinuria: a complex interplay between unique players. Adv Chronic Kidney Dis. 2011;18:233-242.
28. Singh A, Satchell SC. Microalbuminuria: causes and implications. Pe-diatr Nephrol. 2011;26:1957-1965.
29. Singh A, Friden V, Dasgupta I, et al. High glucose causes dysfunction of the human glomerular endothelial glycocalyx. Am J Physiol Renal Phys-iol. 2011;300:F40-F48.
30. Smith ER, Cai MM, McMahon LP, et al. The value of simultaneous measurements of urinary albumin and total protein in proteinuric patients. Nephrol Dial Transplant. 2012;27:1534-1541.
31. Barzilay JI, Fitzpatrick AL, Luchsinger J, et al. Albuminuria and dementia in the elderly: a community study. Am J Kidney Dis. 2008;52:216-226.
32. Jassal SK, Kritz-Silverstein D, Barrett-Connor E. A prospective study of albuminuria and cognitive function in older adults: the Rancho Bernardo study. Am J Epidemiol. 2010;171:277-286.
33. Joosten H, Izaks GJ, Slaets JP, et al. Association of cognitive function with albuminuria and eGFR in the general population. Clin J Am Soc Nephrol. 2011;6:1400-1409.
34. Vupputuri S, Shoham DA, Hogan SL, et al. Microalbuminuria, peripheral artery disease, and cognitive function. Kidney Int. 2008;73:341-346.
35. Weiner DE, Bartolomei K, Scott T, et al. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am J Kidney Dis. 2009;53:438-447.
36. Maione A, Navaneethan SD, Graziano G, et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-And macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011;26:2827-2847.
37. Barzilay JI, Gao P, O'Donnell M, et al. Albuminuria and decline in cognitive function: the ONTARGET/TRANSCEND studies. Arch Intern Med. 2011;171:142-150.
38. Burdo TH, Weiffenbach A, Woods SP, et al. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS. 2013;27:1387-1395.
39. Ances BM, Vaida F, Yeh MJ, et al. HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis. 2010;201:336-340.
40. McMurtray A, Nakamoto B, Shikuma C, et al. Small-vessel vascular disease in human immunodeficiency virus infection: the Hawaii aging with HIV cohort study. Cerebrovasc Dis. 2007;24:236-241.
41. Feng L, Yap KB, Yeoh LY, et al. Kidney function and cognitive and functional decline in elderly adults: findings from the Singapore longitudinal aging study. J Am Geriatr Soc. 2012;60:1208-1214.
42. Kurella Tamura M, Wadley V, Yaffe K, et al. Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis. 2008;52:227-234.
43. Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308: 2349-2360.
44. Inrig JK, Gillespie BS, Patel UD, et al. Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater-than-normal estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2007;2:1215-1222.
45. Shlipak MG, Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369: 932-943.
46. Ng DK, Jacobson LP, Brown TT, et al. HIV therapy, metabolic and cardiovascular health are associated with glomerular hyperfiltration among men with and without HIV infection. AIDS. 2014;28:377-386.
47. Ellis RJ, Evans SR, Clifford DB, et al. Clinical validation of the Neuro-Screen. JNeurovirol. 2005;11:503-511.
48. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993;43:2245-2252.
49. Wachtman LM, Skolasky RL, Tarwater PM, et al. Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus-Associated dementia. Arch Neurol. 2007;64:1264-1272.
50. Bruggeman LA, O'Toole JF, Ross MD, et al. Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol. 2014;25:634-644.
51. Gupta SK, Komarow L, Gulick RM, et al. Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects. J Infect Dis. 2009;200:614-618.
52. Gupta SK, Smurzynski M, Franceschini N, et al. The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. Antivir Ther. 2009;14:543-549.